CIPLA and SBP Group signed an exclusive licensing agreement for the HER2 bispecific antibody conjugate drug TQB2102.

Zhitongcaijing · 1d ago
CIPLA and SBP Group signed an exclusive licensing agreement for the HER2 bispecific antibody conjugate drug TQB2102.